Allarity Therapeutics Inc. (ALLR)
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nutriband CEO Publishes Letter to Shareholders
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
Shareholder Alert: The Ademi Firm investigates whether FONAR Corporation is obtaining a Fair Price for its Public Shareholders
Haw Par Corporation Limited - Announcement
INSP INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Inspire Medical Systems, Inc.
FONAR Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of FONAR Corporation - FONR